Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Macauley, Matthew
  • Pfrengle, F.
  • Rademacher, C.
  • Nycholat, C. M.
  • Gale, Andrew
  • von Drygalski, Annette
  • Paulson, James

publication date

  • July 2013

journal

  • Journal of Clinical Investigation  Journal

abstract

  • Antibodies confer humoral immunity but can also be harmful when they target an autoantigen, alloantigen, allergen, or biotherapeutic. New strategies are needed for antigen-specific suppression of undesired antibody responses, particularly to T cell-dependent protein antigens, because they elicit T cell help. Here we show that liposomal nanoparticles, displaying both antigen and glycan ligands of the inhibitory coreceptor CD22, induce a tolerogenic program that selectively causes apoptosis in mouse and human B cells. These SIGLEC-engaging tolerance-inducing antigenic liposomes (STALs, where SIGLEC is defined as sialic acid-binding Ig-like lectin) induced robust antigen-specific tolerance to protein antigens in mice, preventing subsequent immune response to challenge with the same antigen. Since development of inhibitory antibodies to FVIII is a serious problem in treatment of hemophilia A patients, we investigated the potential of this approach for inducing tolerance to FVIII in a hemophilia mouse model. STALs prevented formation of inhibitory FVIII antibodies, allowing for effective administration of FVIII to hemophilia mice to prevent bleeding. These findings suggest that STALs could be used to eliminate or prevent harmful B cell-mediated immune responses.

subject areas

  • Animals
  • Antigens
  • Apoptosis
  • B-Lymphocytes
  • Calcium Signaling
  • Factor VIII
  • Hemophilia A
  • Humans
  • Immune Tolerance
  • Ligands
  • Liposomes
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Sialic Acid Binding Ig-like Lectin 2
  • Sialic Acids
scroll to property group menus

Identity

PubMed Central ID

  • PMC3706185

International Standard Serial Number (ISSN)

  • 0021-9738

Digital Object Identifier (DOI)

  • 10.1172/jci69187

PubMed ID

  • 23722906
scroll to property group menus

Additional Document Info

start page

  • 3074

end page

  • 3083

volume

  • 123

issue

  • 7

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support